Prostate Cancer Clinical Trials
Castrate-Resistant Prostate Cancer (CRPC)
Learn More About Prostate Cancer
For general information on prostate cancer (including risk factors, symptoms, diagnosis, and treatment) visit the Cancer Council’s website:
General Enquiries
For general questions about trial availability, eligibility, or the referral process, please contact us using the form below. Our team will respond as soon as possible.
| Protocol Number | Cancer Type | Study Name | Intervention | Mechanism of Action | Recruitment Status | Sponsor | ClinicalTrials.gov ID | Click to Enquire |
|---|---|---|---|---|---|---|---|---|
| AWT020-001 | Castrate-Resistant Prostate Cancer | A Phase 1/2, First-in-human, Open-label Study of Single-agent AWT020 in Patients With Progressive Locally Advanced or Metastatic Cancer | Immunotherapy | Anti-PD1 IL-2 BiTE. | Open - Recruiting | Anwita Biosciences | NCT06092580 | Enquire Now |
| HRS-5041-103 | Castrate-Resistant Prostate Cancer | A Phase I, Open-label, Multi-Center, Non-Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer | Targeted | AR-PROTAC molecule - AR degrader | Open - Recruiting | Atridia Pty Ltd | NCT06830850 | Enquire Now |
| PSMA-007-001 | Castrate-Resistant Prostate Cancer | A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer | Immunotherapy | Inhibitor of the pH-sensing G-protein-coupled receptor 65 | Open - Recruiting | Janux Therapeutics | NCT05519449 | Enquire Now |
| DM002001 | Castrate-Resistant Prostate Cancer | A Phase I, Multicentre, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM002 in Patients With Advanced Solid Tumors | Antibody Drug Conjugate | ADC targeting MUC1 and HER3 | Open - Recruiting | Xadcera Biopharmaceutical (Suzhou) Co., Ltd. | NCT06751329 | Enquire Now |
| PTT-4256-01 | Castrate-Resistant Prostate Cancer | A Modular, Open Label, Dose Finding, Phase 1/2 Clinical Trial in Patients With Solid Tumours to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of PTT-4256. | Immunotherapy | ADC targeting a tissue factor. | Open - Recruiting | Pathios Therapeutics Pty Ltd | NCT06634849 | Enquire Now |
| ADCE-T02-01 | Castrate-Resistant Prostate Cancer | First-in-Human, Phase 1 Study of ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors | Antibody Drug Conjugate | Intratumoral (IT) injection. PC7A nanoparticles loaded with cGAMP. Stimulator of interferon genes. | Open - Recruiting | Adcendo ApS | NCT06597721 | Enquire Now |